title: Renal cell carcinoma metastatic to the tongue: a case report and review of the literature.
abstract: Renal cell carcinoma (RCC) metastatic to the head and neck region is quite rare. This report describes a case of RCC metastatic to the oral tongue presenting initially with a renal mass that evaded diagnosis by biopsy examination of the primary lesion and was eventually established as a papillary type RCC by lingual biopsy examination. The tongue mass progressed rapidly despite chemotherapy with interferon-α2b, caused difficulties with oral food intake, and thus necessitated removal by partial glossectomy. Treatment alternatives for lingual RCC metastasis include surgical resection for major functional impairment, risk of airway compromise, or massive hemorrhage. Radiotherapy might be useful and should be considered for specific patients. Lingual metastasis from RCC usually predicts poor survival.
authors.affiliation: Resident, Department of Otorhinolaryngology, Hacettepe University School of Medicine, Ankara, Turkey. Electronic address: ozan.altuntas@gmail.com.
authors.forename: Ozan
authors.initials: O
authors.lastname: Altuntaş
authors.affiliation: Attending Physician, Department of Oncology, Gaziantep Dr Ersin Arslan State Hospital, Gaziantep, Turkey.
authors.forename: İbrahim
authors.initials: İ
authors.lastname: Petekkaya
authors.affiliation: Associate Professor, Department of Otorhinolaryngology, Hacettepe University School of Medicine, Ankara, Turkey.
authors.forename: Nilda
authors.initials: N
authors.lastname: Süslü
authors.affiliation: Professor, Department of Medical Oncology, Hacettepe University School of Medicine, Anakara, Turkey.
authors.forename: İbrahim
authors.initials: İ
authors.lastname: Güllü
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy / Q000379:methods; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000556:secondary*; D005500:Follow-Up Studies; D005927:Glossectomy / Q000379:methods; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D064847:Multimodal Imaging / Q000379:methods; D009361:Neoplasm Invasiveness; D010166:Palliative Care; D049268:Positron-Emission Tomography / Q000379:methods; D011758:Pyrroles / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed / Q000379:methods; D014062:Tongue Neoplasms / Q000473:pathology / Q000556:secondary*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011758:Pyrroles; D011994:Recombinant Proteins; D000077210:Sunitinib